Lisata Therapeutics (NASDAQ:LSTA – Get Rating) and Ontrak (NASDAQ:OTRK – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends.
Institutional & Insider Ownership
6.0% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 49.8% of Ontrak shares are owned by institutional investors. 2.2% of Lisata Therapeutics shares are owned by insiders. Comparatively, 46.6% of Ontrak shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Get Lisata Therapeutics alerts:Volatility & Risk
Lisata Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, Ontrak has a beta of 2.16, indicating that its share price is 116% more volatile than the S&P 500.
Earnings and Valuation
This table compares Lisata Therapeutics and Ontrak's top-line revenue, earnings per share and valuation.| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lisata Therapeutics | N/A | N/A | -$27.47 million | ($12.23) | -0.30 |
| Ontrak | $84.13 million | 0.30 | -$37.14 million | ($3.38) | -0.28 |
Lisata Therapeutics has higher earnings, but lower revenue than Ontrak. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Ontrak, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Lisata Therapeutics and Ontrak, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lisata Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
| Ontrak | 0 | 0 | 0 | 0 | N/A |
Lisata Therapeutics presently has a consensus target price of $15.00, suggesting a potential upside of 313.79%. Ontrak has a consensus target price of $2.27, suggesting a potential upside of 141.78%. Given Lisata Therapeutics' higher possible upside, analysts plainly believe Lisata Therapeutics is more favorable than Ontrak.
Profitability
This table compares Lisata Therapeutics and Ontrak's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lisata Therapeutics | N/A | -29.53% | -27.96% |
| Ontrak | -279.90% | -183.58% | -92.71% |
About Lisata Therapeutics
(Get Rating)
Lisata Therapeutics, Inc. develops biopharmaceuticals. It is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. It is designed to modify the tumor microenvironment by activating a novel uptake pathway that allows anti-cancer drugs to penetrate solid tumors more effectively. The company is headquartered in Basking Ridge, NJ.
About Ontrak
(Get Rating)
Ontrak, Inc. engages in the provision of data analytics based behavioral health management and integrated treatment services to health plans. It offers services through its Ontrak platform solution, which is designed to improve member health, and at the same time, lower costs to the insurer for underserved populations where behavioral health conditions cause or exacerbate co-existing medical conditions. The company was founded by Terren S. Peizer in February 2003 and is headquartered in Santa Monica, CA.
Receive News & Ratings for Lisata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lisata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.